Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN SODIUM versus UTICILLIN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN SODIUM versus UTICILLIN VK.
AMPICILLIN SODIUM vs UTICILLIN VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Uticillin VK (penicillin V potassium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) in the bacterial cytoplasmic membrane, thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
1-2 g IV/IM every 4-6 hours for serious infections; maximum 12 g/day.
250-500 mg orally every 6-8 hours for 10 days for streptococcal pharyngitis; 250-500 mg orally every 6 hours for pneumococcal infections.
None Documented
None Documented
Terminal elimination half-life ~1 hour in healthy adults; prolonged to 2–5 hours in renal impairment (CrCl <10 mL/min) and up to 7–20 hours in anuria; neonatal half-life 2–4 hours.
0.5-1.0 hour (prolonged in renal impairment; e.g., up to 10 hours in anuria)
Approximately 90% renal excretion via tubular secretion and glomerular filtration; small biliary excretion (<10%); fecal elimination negligible.
Renal: 70-80% unchanged via tubular secretion and glomerular filtration; biliary/fecal: minor (about 10%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic